Who is sponsoring NCT05427994?

NCT05427994 is sponsored by Asfendiyarov Kazakh National Medical University.

What drugs are being tested in NCT05427994?

Interventions in NCT05427994: National Eye Institute Visual Function Questionnaire.

What condition does NCT05427994 study?

NCT05427994 studies Age-Related Macular Degeneration.

Is NCT05427994 still recruiting?

NCT05427994 is currently completed. Last updated 1 September 2022.

Last reviewed 2022-09-01 · How we verify

NCT05427994

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessing the Quality of Life and Social Support in Age-Related Macular Degeneration Patients

Completed Last updated 1 September 2022

What this trial tests

trial testing National Eye Institute Visual Function Questionnaire in Age-Related Macular Degeneration in 458 participants. Completed in 27 July 2022.

Timeline

5 April 2021

Primary endpoint
27 July 2022

27 July 2022

Quick facts

Lead sponsor	Asfendiyarov Kazakh National Medical University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	458
Start date	5 April 2021
Primary completion	27 July 2022
Estimated completion	27 July 2022
Sites	2 locations across Kazakhstan

Drugs / interventions tested

National Eye Institute Visual Function Questionnaire

Conditions studied

Age-Related Macular Degeneration — all drugs for Age-Related Macular Degeneration →

Sponsor

Asfendiyarov Kazakh National Medical University

Who can join

Adults 30 to 90, any sex, with Age-Related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the quality of life of AMD patients related to vision using the short version of the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25), patients' social support, and their relationship with demographic and clinical variables.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Endometrial thickness and live birth rates after IVF: a systematic review.
Moshkalova G, Karibayeva I, Kurmanova A, Mamedalieva N, et al · · 2023 · cited 8× · PMID 37326261 · DOI 10.23750/abm.v94i3.14437
Assessing the quality of life in age-related macular degeneration patients: a cross-sectional study in Kazakhstan.
Ismayilova I, Turdaliyeva B, Aldasheva N, Veselovskaya N. · · 2022 · cited 2× · PMID 36533748 · DOI 10.23750/abm.v93i6.13580

Verify or expand the search:

Other recruiting trials for Age-Related Macular Degeneration

Currently open trials in the same condition.

NCT07440225 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) · Phase 2, PHASE3 · recruiting
NCT06619405 — AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance · NA · recruiting
NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
NCT06662162 — Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration · NA · recruiting

Other Asfendiyarov Kazakh National Medical University trials

Trials by the same sponsor.

NCT06953180 — Epigenetics and NCD Prevention in Kazakhstan: Personalized Approaches and Biological Age Prediction · recruiting
NCT06496022 — Comparative Analysis of Risk Factors and Prediction of Frailty Syndrome · active not recruiting
NCT05970861 — Effect of Natural Food on Gut Microbiome and Phospholipid Spectrum of Immune Cells in COVID-19 Patients · NA · completed
NCT05095155 — Study of the Prognostic Role of Gene Polymorphism in the Development of B-cell Leukemias and Lymphomas in Children of Ka · completed
NCT05090644 — Program for the Introduction Into Clinical Practice of the Principles of Personalized and Preventive Medicine Based on t · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05427994 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asfendiyarov Kazakh National Medical University
Last refreshed: 1 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05427994.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing